What is HALO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 11.48B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for HALO?

P/E (TTM) is 28.44 and 52-week range is $61.23 to $134.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s HALO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for HALO?

The company profile lists revenue (TTM) near $1.56B, net income (TTM) near $387M, EPS (TTM) near $3.35 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Halozyme Therapeutics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 113.5M shares outstanding, ISIN US40637H1095 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Halozyme Therapeutics, Inc.

$HALO

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Employees

423

Website

www.halozyme.com/

IPO

2003-01-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US40637H1095

Headquarters

San Diego, California, US

Shares outstanding

113.5M

NAICS sector

Manufacturing

Institutional ownership

112.35%

Browse other companiesFree AI scores and summaries for more stocks